FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)

View source ↗

Summary

The FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited under BLA125057.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Humira (adalimumab)

Snippet

SUPPL AP for HUMIRA (ADALIMUMAB)